Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis

Documents similaires

• Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
  par: Karen L. Jones, et autres
  Publié: (2024)
• Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis
  par: Sara Berg, et autres
  Publié: (2025)
• The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review
  par: Victoria Wen Wei Ng, et autres
  Publié: (2024)
• Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
  par: Deep Dutta, et autres
  Publié: (2024)
• Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis
  par: Ali Esparham, et autres
  Publié: (2024)